(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
PURPOSE: This Phase II trial studies how well imetelstat sodium works in treating younger patient with recurrent or refractory brain tumors. Imetelstat sodium may stop the growth of cancer cell by blocking some of the enzymes needed for cell growth.
Patients between the ages of 1 and 21 with Recurrent High-Grade Glioma, Ependymoma, Medulloblastoma/Primitive Neuroectodermal Tumor and Diffuse Intrinsic Pontine Glioma.
For more information contact:
Cincinnati Children’s Hospital Medical CenterDivision of Hematology/Oncology3333 Burnet Ave., Cincinnati, OH 45229-3039Phone: firstname.lastname@example.org
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center